Literature DB >> 1440493

The prevalence of factor XII deficiency in 103 orally anticoagulated outpatients suffering from recurrent venous and/or arterial thromboembolism.

W M Halbmayer1, C Mannhalter, C Feichtinger, K Rubi, M Fischer.   

Abstract

One hundred and three patients suffering from recurrent venous thrombosis, recurrent arterial thromboembolism and/or recurrent myocardial infarction and 50 healthy subjects were tested for Hageman factor (FXII) coagulant activity and antigen. Among the 103 patients we identified 15 subjects with FXII deficiency (15%), 3 with protein C deficiency (3%) and 3 with protein S deficiency (3%). Combined FXII and protein C, protein S or antithrombin III deficiency was not observed. The 103 patients were divided into subgroups according to the type of thrombotic complication. Among patients with exclusively recurrent venous thromboembolism 8% (p = 0.153) were deficient in FXII. Among patients suffering from recurrent arterial thromboembolism and/or myocardial infarction, the incidence of FXII deficiency was significantly higher (20%, p less than 0.003). In 67% of the patients with FXII deficiency a positive family history of thrombosis could be established. In contrast, only 32% of all venous and 28% of all arterial thrombosis patients had a positive family history. We believe that reduced levels of FXII should be considered as a risk factor in the development of thromboembolism. Consequently, more attention should be payed to the measurement of FXII when evaluating thromboembolic risk factors especially in cases of recurrent arterial thromboembolism and/or myocardial infarction.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1440493

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  16 in total

1.  Factor XII deficiency and recurrent sixth nerve palsy.

Authors:  A Kipioti; O C Backhouse; P M Jacobs; M R Howard
Journal:  Br J Ophthalmol       Date:  2003-03       Impact factor: 4.638

2.  Relationship between factor XII deficiency and thrombosis: the debate is still open?

Authors:  Gianfranco Lessiani; Angela Falco; Elvira Nicolucci; Giancarlo Rolandi; Giovanni Davì
Journal:  J Thromb Thrombolysis       Date:  2009-04-08       Impact factor: 2.300

3.  A quantitative-trait locus in the human factor XII gene influences both plasma factor XII levels and susceptibility to thrombotic disease.

Authors:  José Manuel Soria; Laura Almasy; Juan Carlos Souto; Delphine Bacq; Alfonso Buil; Alexandra Faure; Elisabeth Martínez-Marchán; José Mateo; Montserrat Borrell; William Stone; Mark Lathrop; Jordi Fontcuberta; John Blangero
Journal:  Am J Hum Genet       Date:  2002-01-22       Impact factor: 11.025

Review 4.  Factor XI and XII as antithrombotic targets.

Authors:  Felicitas Müller; David Gailani; Thomas Renné
Journal:  Curr Opin Hematol       Date:  2011-09       Impact factor: 3.284

Review 5.  Factor XII: what does it contribute to our understanding of the physiology and pathophysiology of hemostasis & thrombosis.

Authors:  Evi Stavrou; Alvin H Schmaier
Journal:  Thromb Res       Date:  2010-03       Impact factor: 3.944

Review 6.  In vivo roles of factor XII.

Authors:  Thomas Renné; Alvin H Schmaier; Katrin F Nickel; Margareta Blombäck; Coen Maas
Journal:  Blood       Date:  2012-09-19       Impact factor: 22.113

Review 7.  The many faces of the contact pathway and their role in thrombosis.

Authors:  Rebecca S Woodruff; Bruce Sullenger; Richard C Becker
Journal:  J Thromb Thrombolysis       Date:  2011-07       Impact factor: 2.300

Review 8.  Plasma contact factors as therapeutic targets.

Authors:  Benjamin F Tillman; Andras Gruber; Owen J T McCarty; David Gailani
Journal:  Blood Rev       Date:  2018-04-12       Impact factor: 8.250

9.  Combined cis-regulator elements as important mechanism affecting FXII plasma levels.

Authors:  Maria Sabater-Lleal; Miguel Chillón; Carolina Mordillo; Angel Martínez; Estel Gil; José Mateo; John Blangero; Laura Almasy; Jordi Fontcuberta; José Manuel Soria
Journal:  Thromb Res       Date:  2009-09-27       Impact factor: 3.944

10.  Coagulation factors IX through XIII and the risk of future venous thrombosis: the Longitudinal Investigation of Thromboembolism Etiology.

Authors:  Mary Cushman; Ellen S O'Meara; Aaron R Folsom; Susan R Heckbert
Journal:  Blood       Date:  2009-07-17       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.